Navigation Links
Inverness Medical Innovations Announces Fourth Quarter 2008 Results
Date:2/18/2009

WALTHAM, Mass., Feb. 18 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, today announced its financial results for the quarter ended December 31, 2008.

In the fourth quarter of 2008, the Company recorded net revenue of $459.3 million compared to net revenue of $288.0 million in the fourth quarter of 2007, an increase of 59%. The revenue increase was primarily due to $114.0 million of incremental revenue provided by our Health Management segment, along with $34.6 million of incremental revenue contributed by our other recently acquired businesses and organic growth which, on a currency adjusted basis, was approximately 10.7% in our Professional Diagnostics segment.

For the fourth quarter of 2008, the net income prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") was $16.4 million, or $0.14 per diluted common share, compared to net loss of $15.8 million, or $0.24 per diluted common share, for the fourth quarter of 2007. The Company reported adjusted cash basis net income of $60.2 million, or $0.66 per diluted common share, for the fourth quarter of 2008, compared to adjusted cash basis net income of $27.6 million, or $0.40 per diluted common share, for the fourth quarter of 2007.

The Company's GAAP results for the fourth quarter of 2008 include amortization of $60.3 million, $5.0 million of restructuring charges and $6.7 million of stock-based compensation expense. GAAP results for the fourth quarter of 2007 include amortization of $28.0 million, the write-off of $4.8 million of in-process research and development acquired in connection with our acquisition of Diamics, $5.2 million of restructuring charges, $5.3 million of stock-based compensation expense, a $0.8 million charge related to the write-up to fair market value of inventory acquired in connection with the Cholestech and HemoSense acquisitions, and an unrealized foreign currency loss of $3.9 million associated with a cash escrow established in connection with the acquisition of BBI Holdings Plc.. These amounts, net of tax, have been excluded from the adjusted cash basis net income per common share for the respective quarters.

A detailed reconciliation of the Company's adjusted cash basis net income, which is a non-GAAP financial measure, to net income under GAAP, as well as a discussion regarding this non-GAAP financial measure, is included in the schedules to this press release.

The Company will host a conference call beginning at 10:00 a.m. (Eastern Time) today, February 18, 2009, to discuss these results as well as other corporate matters. During the conference call, the Company may answer questions concerning business and financial developments and trends and other business and financial matters. The Company's responses to these questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been previously disclosed.

The conference call may be accessed by dialing 706-679-1656 (domestic and international), an access code is not required, or via a link on the Inverness website at www.invernessmedical.com. It is also available via link at https://event.meetingstream.com/r.htm?e=134985&s=1&k=91C3084D8CBF362549FF6D6A8D9F0BDC using Real Player or Windows Media. An on-demand web cast of the call will be available at the Inverness website (www.invernessmedical.com/News.cfm) two hours after the end of the call and will be accessible for 30 days. Additionally, reconciliations to non-GAAP financial measures not included in this press release that may be discussed during the call will also be available at the same website beginning shortly before the conference call and will continue to be available on this website for 30 days.

For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life at home. Inverness' global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

               Inverness Medical Innovations, Inc. and Subsidiaries
               Condensed Consolidated Statements of Operations and
              Reconciliation to Non-GAAP Adjusted Cash Basis Amounts
                       (in $000s, except per share amounts)


                                      Year Ended December 31, 2008
                                      ----------------------------
                                                                 Non-GAAP
                                                                 Adjusted
                                           Non-GAAP                Cash
                               GAAP      Adjustments             Basis (a)
                               ----      -----------             ---------

    Net product sales and
     services revenue       $1,645,600         $-               $1,645,600
    License and royalty
     revenue                    25,826          -                   25,826
    Net revenue              1,671,426          -                1,671,426
    Cost of sales              810,867    (64,780)(b)(c)(d)(e)     746,087
      Gross profit             860,559     64,780                  925,339
      Gross margin                  51%                                 55%

    Operating expenses:
      Research and
       development             111,828    (15,586)(b)(c)(d)         96,242
      Purchase of in-
       process research
       and development               -          -                        -
      Selling, general
       and administrative      684,879   (198,865)(b)(c)(d)        486,014
    Total operating
     expenses                  796,707   (214,451)                 582,256
         Operating (loss)
          income                63,852    279,231                  343,083
    Interest and other
     income (expense), net    (103,356)     8,762 (c)(i)           (94,594)
    Income tax (benefit)
     provision                 (16,686)    99,242 (j)               82,556
    Equity earnings of
     unconsolidated
     entities, net of tax        1,050      8,183 (b)(c)             9,233
      Net (loss) income       $(21,768)  $196,934                 $175,166

    Preferred stock
     dividends                $(13,989)                            (13,989)

      Net (loss) income
       available to common
       stockholders -
       basic                  $(35,757)                           $161,177

    Net (loss) income per
     common share:
      Basic                     $(0.46)                              $2.07
      Diluted                   $(0.46)(k)                           $1.97 (l)

    Weighted average
     common shares - basic      77,778                              77,778
    Weighted average
     common shares -
     diluted                    77,778 (k)                          83,376 (l)




                                      Year Ended December 31, 2007
                                      ----------------------------
                                                                Non-GAAP
                                                                Adjusted
                                           Non-GAAP               Cash
                               GAAP       Adjustments           Basis (a)
                               ----       -----------           ---------

    Net product sales and
     services revenue         $817,561         $-                 $817,561
    License and royalty
     revenue                    21,979          -                   21,979
    Net revenue                839,540          -                  839,540
    Cost of sales              445,813    (34,877)(b)(c)(d)(e)     410,936
      Gross profit             393,727     34,877                  428,604
      Gross margin                  47%                                 51%

    Operating expenses:
      Research and
       development              69,547     (7,597)(b)(c)(d)         61,950
      Purchase of in-
       process research
       and development         173,825   (173,825)(f)                    -
      Selling, general
       and administrative      326,208    (94,021)(b)(c)(d)        232,187
    Total operating
     expenses                  569,580   (275,443)                 294,137
         Operating (loss)
          income              (175,853)   310,320                  134,467
    Interest and other
     income (expense), net     (74,251)    17,557 (g)(h)           (56,694)
    Income tax (benefit)
     provision                    (979)    14,923 (j)               13,944
    Equity earnings of
     unconsolidated
     entities, net of tax        4,372        448 (b)                4,820
      Net (loss) income      $(244,753)  $313,402                  $68,649

    Preferred stock
     dividends                      $-                                  $-

      Net (loss) income
       available to common
       stockholders -
       basic                 $(244,753)                            $68,649

    Net (loss) income per
     common share:
      Basic                     $(4.75)                              $1.33
      Diluted                   $(4.75)(k)                           $1.27(m)

    Weighted average
     common shares - basic      51,510                              51,510
    Weighted average
     common shares -
     diluted                    51,510(k)                           54,236(m)


    (a) In calculating net income or loss on an adjusted cash basis, the
        Company excludes from net income or loss (i) certain non-cash
        charges, including amortization expense and stock-based compensation
        expense, (ii) non-recurring charges and income, and (iii) certain
        other charges and income that have a significant positive or negative
        impact on results yet do not occur on a consistent or regular basis
        in its business.  In determining whether a particular item meets one
        of these criteria, management considers facts and circumstances that
        it believes are relevant.  Management believes that excluding such
        charges and income from income or loss allows investors and
        management to evaluate and compare the Company's operating results
        from continuing operations from period to period in a meaningful and
        consistent manner.  Due to the frequency of their occurrence in its
        business, the Company does not adjust net income or loss for the
        costs associated with litigation, including payments made or received
        through settlements.  It should be noted that "net income or loss on
        an adjusted cash basis" is not a standard financial measurement under
        accounting principles generally accepted in the United States of
        America ("GAAP") and should not be considered as an alternative to net
        income or loss or cash flow from operating activities, as a measure of
        liquidity or as an indicator of operating performance or any measure
        of performance derived in accordance with GAAP.  In addition, all
        companies do not calculate non-GAAP financial measures in the same
        manner and, accordingly, "net income or loss on an adjusted cash
        basis" presented in this press release may not be comparable to
        similar measures used by other companies.

    (b) Amortization expense of $215.3 million and $64.6 million for the year
        2008 and 2007 GAAP results, respectively, including $43.4 million and
        $24.1 million charged to cost of sales, $3.7 million and $2.9 million
        charged to research and development, $167.3 million and $37.2 million
        charged to selling, general and administrative expense, in the
        respective periods, with $0.9 million and $0.4 million charged through
        equity earnings of unconsolidated entities, net of tax, during the
        respective periods.

    (c) Restructuring charge associated with the decision to close facilities
        of $50.7 million and $6.7 million for the year 2008 and 2007 GAAP
        results, respectively.  The $50.7 million charge for the year ended
        December 31, 2008 included $17.9 million charged to cost of sales,
        $7.2 million charged to research and development, $11.3 million
        charged to selling, general and administrative expense, $7.1 million
        charged to interest expense and $7.2 million charged through equity
        earnings of unconsolidated entities, net of tax.  The $6.7 million
        charge for the year ended December 31, 2007 included $2.0 million
        charged to cost of sales, $2.5 million charged to research and
        development and $2.2 million charged to selling, general and
        administrative expense.  These charges have been excluded from net
        income or loss because they have a significant impact on results yet
        do not occur on a consistent or regular basis in the Company's
        business.

    (d) Compensation costs of $26.4 million and $57.4 million associated with
        stock-based compensation expense for the year 2008 and 2007 GAAP
        results, respectively, including $1.5 million and $0.6 million charged
        to cost of sales, $4.6 million and $2.2 million charged to research
        and development and $20.3 million and $54.6 million charged to
        selling, general and administrative.  The $54.6 million charged to
        selling, general and administrative during the year-ended December 31,
        2007 includes $45.2 million of costs associated with stock option
        acceleration and conversion in connection with our acquisition of
        Biosite, Inc.

    (e) A write-off in the amount of $2.0 million and $8.2 million during the
        year ended December 31, 2008 and 2007, respectively, relating to
        inventory write-ups recorded in connection with the acquisitions of
        Panbio Limited and BBI Holdings Plc. during the first quarter of 2008
        and Biosite, Inc., Cholestech Corp. and HemoSense, Inc. during the
        second, third and fourth quarters of 2007, respectively.

    (f) Purchase of in-process research and development during the year ended
        December 31, 2007 includes a write-off of $169.0 million and $4.8
        million associated with the value of in-process research and
        development costs incurred in connection with our acquisitions of
        Biosite, Inc. and Diamics, Inc., respectively.

    (g) Charges totaling $15.6 million associated with the write-off of debt
        origination costs and a prepayment premium paid upon early
        extinguishment of related debt during the year ended December 31,
        2007, in conjunction with our financing arrangements.

    (h) A $3.9 million unrealized foreign currency loss associated with a cash
        escrow established in connection with the acquisition of BBI Holdings
        Plc, partially offset by a $1.9 million foreign currency gain realized
        on the settlement of intercompany notes.

    (i)  A $1.7 million net realized foreign currency loss associated with a
        cash escrow established in connection with the acquisition of BBI
        Holdings Plc.

    (j) Tax effect on adjustments as discussed above in notes (b), (c), (d),
        (e), (f), (g), (h) and (i).

    (k) For the year ended December 31, 2008 and 2007, potential dilutive
        shares were not used in the calculation of diluted net loss per
        common share under GAAP because inclusion thereof would be
        antidilutive.

    (l) Included in the weighted average diluted common shares for the
        calculation of net income per common share for the year ended
        December 31, 2008, on an adjusted cash basis, are dilutive shares
        consisting of 2,188,000 common stock equivalent shares from the
        potential exercise of stock options and warrants and potential
        dilutive shares consisting of 3,411,000 common stock equivalent
        shares from the potential conversion of convertible debt securities.
        The diluted net income per common share calculation for the year
        ended December 31, 2008, on an adjusted cash basis, includes the
        add back of interest expense related to the convertible debt of $2.8
        million resulting in net income available to common stockholders of
        $164.0 million. Potential dilutive shares consisting of 6,681,000
        common stock equivalent shares from the potential conversion of
        Series B convertible preferred stock for the year ended December 31,
        2008 were not used in the calculation of diluted net income per
        common share, on an adjusted cash basis, because inclusion thereof
        would be antidilutive.

    (m) Included in the weighted average diluted common shares for the
        calculation of diluted net income per common share for the year ended
        December 31, 2007, on an adjusted cash basis, are dilutive shares
        consisting of 2,726,000 common stock equivalent shares from the
        potential exercise of stock options and awards and warrants.  The
        diluted net income per common share calculation  for the year ended
        December 31, 2007, on an adjusted cash basis, does not include
        1,807,000 common stock equivalent shares from the potential
        conversion of convertible debt, as inclusion thereof would be
        antidilutive.



             Inverness Medical Innovations, Inc. and Subsidiaries
             Condensed Consolidated Statements of Operations and
            Reconciliation to Non-GAAP Adjusted Cash Basis Amounts
                     (in $000s, except per share amounts)


                               Three Months Ended December 31, 2008
                               ------------------------------------
                                                             Non-GAAP
                                                             Adjusted
                                        Non-GAAP               Cash
                             GAAP      Adjustments           Basis (a)
                             ----      -----------           ---------

    Net product sales
     and services revenue   $454,916         $-               $454,916
    License and royalty
     revenue                   4,350          -                  4,350
    Net revenue              459,266          -                459,266
    Cost of sales            213,347    (11,220) (b)(c)(d)     202,127
      Gross profit           245,919     11,220                257,139
      Gross margin                54%                               56%

    Operating expenses:
      Research and
       development            25,402     (2,506) (b)(c)(d)      22,896
      Purchase of in-
       process research
       and development             -          -                      -
      Selling, general
       and administrative    188,192    (56,579) (b)(c)(d)     131,613
    Total operating
     expenses                213,594    (59,085)               154,509
         Operating income     32,325     70,305                102,630
    Interest and other
     income (expense),
     net                     (19,205)       147 (c)            (19,058)
    Income tax (benefit)
     provision                (3,412)    28,192 (h)             24,780
    Equity earnings of
     unconsolidated
     entities, net of tax       (119)     1,505 (b)(c)           1,386
      Net income (loss)      $16,413    $43,765                $60,178

    Preferred stock
     dividends               $(5,490)                           (5,490)

      Net income (loss)
       available to
       common
       stockholders -
       basic                 $10,923                           $54,688

    Net income (loss)
     per common share:
      Basic                    $0.14                             $0.70
      Diluted                  $0.14 (i)                         $0.66 (k)

    Weighted average
     common shares -
     basic                    78,217                            78,217
    Weighted average
     common shares -
     diluted                  78,941 (i)                        92,853 (k)


                               Three Months Ended December 31, 2007

                                                              Non-GAAP
                                                              Adjusted
                                          Non-GAAP              Cash
                             GAAP        Adjustments          Basis (a)
                             ----        -----------          ---------

    Net product sales
     and services revenue   $283,040         $-                283,040
    License and royalty
     revenue                   4,920          -                  4,920
    Net revenue              287,960          -                287,960
    Cost of sales            149,209    (13,266)(b)(c)(d)(e)   135,943
      Gross profit           138,751     13,266                152,017
      Gross margin                48%                               53%

    Operating expenses:
      Research and
       development            24,898     (3,838)(b)(c)(d)       21,060
      Purchase of in-
       process research
       and development         4,825     (4,825)(f)                  -
      Selling, general
       and administrative    102,200    (22,100)(b)(c)(d)       80,100
    Total operating
     expenses                131,923    (30,763)               101,160
         Operating income      6,828     44,029                 50,857
    Interest and other
     income (expense),
     net                     (26,835)     3,894 (g)            (22,941)
    Income tax (benefit)
     provision                (2,529)     4,676 (h)              2,147
    Equity earnings of
     unconsolidated
     entities, net of tax      1,706        112 (b)              1,818
      Net income (loss)     $(15,772)   $43,359                $27,587

    Preferred stock
     dividends                    $-                                $-

      Net income (loss)
       available to
       common
       stockholders -
       basic                $(15,772)                          $27,587

    Net income (loss)
     per common share:
      Basic                   $(0.24)                            $0.42
      Diluted                 $(0.24) (j)                         0.40 (l)

    Weighted average
     common shares -
     basic                    65,525                            65,525
    Weighted average
     common shares -
     diluted                  65,525 (j)                        69,578 (l)


    (a) In calculating net income or loss on an adjusted cash basis, the
        Company excludes from net income or loss (i) certain non-cash
        charges, including amortization expense and stock-based compensation
        expense, (ii) non-recurring charges and income, and (iii) certain
        other charges and income that have a significant positive or
        negative impact on results yet do not occur on a consistent or
        regular basis in its business.  In determining whether a particular
        item meets one of these criteria, management considers facts and
        circumstances that it believes are relevant.  Management believes
        that excluding such charges and income from income or loss allows
        investors and management to evaluate and compare the Company's
        operating results from continuing operations from period to period
        in a meaningful and consistent manner.  Due to the frequency of
        their occurrence in its business, the Company does not adjust net
        income or loss for the costs associated with litigation, including
        payments made or received through settlements.  It should be noted
        that "net income or loss on an adjusted cash basis" is not a
        standard financial measurement under accounting principles generally
        accepted in the United States of America ("GAAP") and should not be
        considered as an alternative to net income or loss or cash flow from
        operating activities, as a measure of liquidity or as an indicator
        of operating performance or any measure of performance derived in
        accordance with GAAP.  In addition, all companies do not calculate
        non-GAAP financial measures in the same manner and, accordingly, "net
        income or loss on an adjusted cash basis" presented in this press
        release may not be comparable to similar measures used by other
        companies.

    (b) Amortization expense of $60.3 million and $28.0 million in the fourth
        quarter of 2008 and 2007 GAAP results, respectively, including $9.2
        million and $10.2 million charged to cost of sales, $1.0 million and
        $0.7 million charged to research and development, $49.9 million and
        $17.0 million charged to selling, general and administrative expense,
        in the respective quarters, with $0.2 million and $0.1 million charged
        through equity earnings of unconsolidated entities, net of tax,
        during the respective quarters.

    (c) Restructuring charge associated with the decision to close facilities
        of $5.0 million and $5.2 million in the fourth quarter of 2008 and
        2007 GAAP results, respectively.  The $5.0 million charge for the
        three months ended December 31, 2008 included $1.5 million charged to
        cost of sales, $0.4 million charged to research and development, $1.7
        million charged to selling, general and administrative expense, $0.1
        million charged to interest expense and $1.3 million charged through
        equity earnings of unconsolidated entities, net of tax.  The $5.2
        million charge for the three months ended December 31, 2007 included
        $2.0 million charged to cost of sales, $2.2 million charged to
        research and development and $1.0 million charged to selling, general
        and administrative expense. These charges have been excluded from net
        income or loss because they have a significant impact on results yet
        do not occur on a consistent or regular basis in the Company's
        business.

    (d) Compensation costs of $6.7 million and $5.3 million associated with
        stock-based compensation expense in the fourth quarter of 2008 and
        2007 GAAP results, respectively, including $0.5 million and $0.3
        million charged to cost of sales, $1.2 million and $0.9 million
        charged to research and development and $5.0 million and $4.1 million
        charged to selling, general and administrative, in the respective
        quarters.

    (e) A write-off in the amount of $0.8 million during the fourth quarter
        of 2007, relating to inventory write-ups recorded in connection with
        the acquisitions of Cholestech Corp. and HemoSense, Inc. during the
        third and fourth quarters, respectively, of 2007.

    (f) Purchase of in-process research and development in the fourth quarter
        of 2007 includes a write-off of $4.8 million associated with the value
        of in-process research and development costs incurred in connection
        with our acquisition of Diamics, Inc.

    (g) A $3.9 million unrealized foreign currency loss associated with a cash
        escrow established in connection with the acquisition of BBI Holdings
        Plc.

    (h) Tax effect on adjustments as discussed above in notes (b), (c), (d),
        (e), (f) and (g).

    (i) Included in the weighted average diluted common shares for the
        calculation of net income per common share on a GAAP basis for the
        three months ended December 31, 2008, are dilutive shares consisting
        of 724,000 common stock equivalent shares from the potential exercise
        of stock options and warrants. Potential dilutive shares consisting of
        3,411,000 common stock equivalent shares from the potential conversion
        of convertible debt securities and potential dilutive shares
        consisting of 10,502,000 common stock equivalent shares from the
        potential conversion of Series B convertible preferred stock were not
        included in the calculation of net income per common share on a GAAP
        basis for the three months ended December 31, 2008 because inclusion
        thereof would be antidilutive.

    (j) For the three months ended December 31, 2007, potential dilutive
        shares were not used in the calculation of diluted net loss per
        common share under GAAP because inclusion thereof would be
        antidilutive.

    (k) Included in the weighted average diluted common shares for the
        calculation of net income per common share for the three months ended
        December 31, 2008, on an adjusted cash basis, are dilutive shares
        consisting of 724,000 common stock equivalent shares from the
        potential exercise of stock options and warrants.  Also included were
        potential dilutive shares consisting of 3,411,000 common stock
        equivalent shares from the potential conversion of convertible debt
        securities and 10,502,000 common stock equivalent shares from the
        potential conversion of Series B convertible preferred stock.  The
        diluted net income per common share calculation for the three months
        ended December 31, 2008, on an adjusted cash basis, includes the add
        back of interest expense related to the convertible debt of $0.7
        million and the add back of preferred stock dividends related to the
        Series B convertible preferred stock resulting in net income available
        to common stockholders of $60.9 million for the three months ended
        December 31, 2008.

    (l) Included in the weighted average diluted common shares for the
        calculation of diluted net income per common share for the three
        months ended December 31, 2007, on an adjusted cash basis, are
        dilutive shares consisting of 4,053,000 common stock equivalent shares
        from the potential exercise of stock options and awards and warrants.
        The diluted net income per common share calculation for the three
        months ended December 31, 2007, on an adjusted cash basis, does not
        include 2,868,000 common stock equivalent shares from the potential
        conversion of convertible debt, as inclusion thereof would be
        antidilutive.



              Inverness Medical Innovations, Inc. and Subsidiaries
                      Condensed Consolidated Balance Sheets
                                   (in $000s)

                                                    December 31, December 31,
                                                           2008         2007
                                                           ----         ----
    ASSETS
    ------
    CURRENT ASSETS:
    Cash and cash equivalents                          $141,324     $414,732
    Restricted cash                                       2,748      141,869
    Marketable securities                                 1,763        2,551
    Accounts receivable, net                            280,608      163,380
    Inventories, net                                    199,131      148,231
    Prepaid expenses and other current assets           196,969       82,211
    Total current assets                                822,543      952,974

    PROPERTY, PLANT AND EQUIPMENT, NET                  284,483      267,880
    GOODWILL AND OTHER INTANGIBLE ASSETS, NET         4,717,704    3,494,174
    DEFERRED FINANCING COSTS AND OTHER ASSETS, NET      130,630      165,731
    Total assets                                     $5,955,360   $4,880,759

    LIABILITIES AND STOCKHOLDERS' EQUITY
    ------------------------------------
    CURRENT LIABILITIES:
    Current portion of notes payable                    $19,509      $21,096
    Other current liabilities                           345,836      257,812
    Total current liabilities                           365,345      278,908

    LONG-TERM LIABILITIES:
    Notes payable, net of current portion             1,501,025    1,366,753
    Deferred tax liability                              462,787      326,128
    Other long-term liabilities                         347,365      322,303
    Total long-term liabilities                       2,311,177    2,015,184


    TOTAL STOCKHOLDERS' EQUITY                        3,278,838    2,586,667
    Total liabilities and stockholders' equity       $5,955,360   $4,880,759




'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET February 18, 2009 to Discuss Fourth Quarter 2008 Results
2. James Roosevelt, Jr. Joins Inverness Medical Innovations Board of Directors
3. Inverness Medical Innovations to Present at the 2009 UBS Global Healthcare Services Conference on February 10, 2009
4. Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008
5. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 13, 2009
6. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
7. Inverness Medical Innovations to Present at RBC Capital Markets 2008 Healthcare Conference on December 11, 2008
8. Inverness Medical Innovations, PrognostiX Sign Distribution Agreement for CardioMPO(TM) Test
9. Inverness Medical Innovations to Present at the Third Annual JMP Securities Healthcare Focus Conference on October 7, 2008
10. Inverness Medical Innovations Announces 4th Generation Rapid HIV Test - Determine(TM) HIV-1/2 Ag/Ab Combo
11. Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Council for Graduate Medical Education (ACGME) that it has received accreditation for its ... accreditation of three residency programs that Memorial is currently pursuing, including Pediatrics and ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of the ... signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. ... a 70% tax credit to individuals and corporations which donate directly to a “rural ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced efforts ... more information about their loan terms and accounts, and more protections for borrowers. ... federal and private loans, has reached $1.3 trillion, with 43 million Americans holding ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... ... 29, 2016 , ... Mobility Designed is redefining mobility with their patent ... M+D Crutch evenly distributes body weight from the elbow to the forearm. In ... crutches than with other crutches. , Co-founders Max and Liliana Younger were inspired to ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... , April 27, 2016 ... accelerator (MR-linac) platform will be the focal point of ... of the European Society for Radiotherapy & Oncology, taking ... MR-linac integrates a state-of-the-art radiotherapy system and a high-field ... to clearly see the patient,s anatomy in real time. ...
(Date:4/27/2016)... 2016 Tie-up with Government hospitals ... to save newborns   Fortis La Femme, ... in collaboration with Breast Milk Foundation (BMF), a non-profit organization ... Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes ... infants and should be available to babies deprived of mother,s ...
(Date:4/27/2016)... Research and Markets has ... Disposables Market 2016-2020"  report to their offering.  ... global anesthesia disposables market is set to ... the period 2016-2020.  Healthcare-acquired infections ... safety. Organizations like the CDC and Public ...
Breaking Medicine Technology: